Comparative Pharmacology
Head-to-head clinical analysis: MAXIDEX versus STERI STAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXIDEX versus STERI STAT.
MAXIDEX vs STERI-STAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAXIDEX (dexamethasone) is a potent glucocorticoid that binds to the glucocorticoid receptor (GR), leading to modulation of gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes. It suppresses immune response through inhibition of cytokine production (e.g., IL-1, IL-2, TNF-alpha) and reduces vasodilation and vascular permeability.
Binds to the 50S ribosomal subunit of bacteria, inhibiting protein synthesis by blocking peptide bond formation and translocation.
One to two drops of the 0.1% ophthalmic suspension into the conjunctival sac every hour during the day and every two hours at night initially; after improvement, reduce to one drop every four hours, then one drop three to four times daily.
Adults: 1 gram intravenously every 8 hours infused over 60 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours for dexamethasone; in ocular tissues, half-life may be prolonged due to local retention, but systemic half-life is short with minimal accumulation.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min).
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for <15% unchanged drug; biliary/fecal elimination of metabolites predominates.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; biliary/fecal elimination is minimal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid